Global Antiretroviral Drugs Market Size & Analysis – Forecasts To 2026 By Drug Class (Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Integrase inhibitors, Nucleoside Analogs, Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Others), By Region (North America, Europe, Asia Pacific, CSA, MEA); Vendor Landscape, Company Market Share & Competitor Analysis Global Antiretroviral Drugs Market Insights The global market for antiretroviral drugs is projected to grow at a high CAGR during the forecast period. The market is primarily driven by factors such as growing prevalence of HIV, improving insurance industry, and availability of efficient drugs. Other factors contributing towards demand for antiretroviral drugs are steps taken by the government to provide better healthcare, growing healthcare expenditure, efforts to reduce cost of treatment and overall awareness about drugs for HIV treatment. However, stringent regulatory environment and requirement of numerous government approvals for antiretroviral drugs is expected to hamper the growth of antiretroviral drugs market.
Antiretroviral Drugs Market: Drug Class Insights Based on drug class, the global antiretroviral drugs market can be segmented into protease inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, nucleoside analogs, multi-class combination drugs, and nucleoside reverse transcriptase inhibitors among others. The multi-class combination drugs segment is estimated to hold the largest market share in terms of revenue in 2018. Combination drugs combine medications from different drug classes into a single drug form, and provide the overall benefits of multiple drug classes. The segment is also projected to grow at the highest CAGR during the forecast period. Antiretroviral Drugs Market: Regional Insights North America is estimated to hold the largest market share in terms of revenue during the forecast period. The market is primarily driven by a well- developed healthcare industry. Government efforts to provide HIV drugs and a higher diagnosis rate are some of the other major factors expected to propel the growth of market in the region. Countries such as the U.S. and Canada are investing heavily in research and development of HIV drugs. The Asia Pacific region is projected to grow at a high CAGR owing to its large population and growing prevalence of HIV in the region. Antiretroviral Drugs Market: Vendor Landscape The report contains a chapter dedicated to vendors operating in the market, covering raw material manufactures, equipment developers, manufacturers, and distributors. The report provides these insights on a regional level. This section of the report entails contact details, experience, products manufactured/supplied, and geographical presence of companies. Antiretroviral Drugs Market Share & Competitor Analysis Major players in the Antiretroviral Drugs Market are Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann- La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Gilead Sciences, Inc., Johnson & Johnson and Cipla Limited among others. In April 2019, the U.S. Food and Drug Administration approved Dovato (dolutegravir and lamivudine) as a regimen for the treatment of HIV infection in adults with no antiretroviral treatment history and suspected substitutions associated with resistance to the individual components of Dovato.
In August 2017, U.S. drug company Mylan received an approval to market antiretroviral drug Avonza in India